Director/PDMR Shareholding

RNS Number : 8380O

Kainos Group plc

11 February 2021

 

The following amendment has been made to the 'Director/PDMR Shareholdings' announcement released on 10 February 2021 at 17:00 under RNS No 6814O.

'Following this notification, Paul Gannon and his Connected Persons have a reportable shareholding of 7,329,008 ordinary shares in the issued share capital of the Company constituting 5.975% of the issued share capital of the Company.'

All other details remain unchanged.

The full amended text is shown below.

10 February 2021

Kainos Group plc

("Kainos" or the "Company")  

Director/PDMR Shareholdings

The Company was notified on 9 February 2021, that Paul Gannon, Director, sold 200,000 ordinary shares in the Company at an aggregated price of £13.35 per ordinary share.

The Company was further notified on 10 February 2021, that Mr Gannon transferred 50,000 ordinary shares in the Company to a Family Partnership for nil consideration.

Following this notification, Paul Gannon and his Connected Persons have a reportable shareholding of 7,329,008 ordinary shares in the issued share capital of the Company constituting 5.975% of the issued share capital of the Company.

Director / PDMR shareholdings

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated
a.	Name	Paul Gannon
2.	Reason for the notification
a.	Position/status	Director
b.	Initial notification /Amendment	Initial
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Kainos Group plc
b.	LEI	213800H2PQMIF3OVZY47
4.(i)	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the Financial instrument/ type of instrument Identification code	Ordinary Shares of £0.005 each KNOS
b.	Nature of the transaction	Sale of Shares
c.	Price(s) and volume(s)	Price(s) Volume(s) £13.35 200,000
d.	Aggregated information ·Aggregated volume ·Price	N/A
e.	Date of the transaction	09- February-2021
f.	Place of the transaction	LSE - Regulated Market - XLON
4.(ii)	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the Financial instrument/ type of instrument Identification code	Ordinary Shares of £0.005 each KNOS
b.	Nature of the transaction	Transfer of shares into a Family Partnership
c.	Price(s) and volume(s)	Price(s) Volume(s) NIL 50,000
d.	Aggregated information ·Aggregated volume ·Price	N/A
e.	Date of the transaction	10-February-2021
f.	Place of the transaction	LSE - Regulated Market - XLON

Kainos Group plc Legal Entity Identifier: 213800H2PQMIF3OVZY47 

Ends

For further information, please contact:

Kainos  via FTI Consulting LLP

Brendan Mooney, Chief Executive Officer

Richard McCann, Chief Financial Officer

Investec Bank plc   [phone]

Patrick Robb / Ben Griffiths

Canaccord Genuity   [phone]

Simon Bridges/ Emma Gabriel

FTI Consulting LLP  [phone]

Matt Dixon / Dwight Burden / Kwaku Aning

About Kainos

Kainos Group plc is a UK-headquartered provider of Digital Services and Digital Platforms. 

The Group's Digital Services include full lifecycle development and support of customised Digital Services for government and commercial customers. Kainos is also the leading European partner for Workday, Inc. ('Workday'), responsible for implementing Workday's innovative Software-as-a-Service (SaaS) platform for enterprise and, now, government customers. 

The Group's Digital Platforms comprise specialised digital platforms in the mobile healthcare and automated testing arenas. Smart is an automated testing platform for Workday customers; Evolve Electronic Medical Records ('EMR') is the market-leading product for the digitisation of patient notes in the Acute sector of the NHS.

Kainos has over 1,700 people across 15 offices in Europe and North America.

Kainos is listed on the London Stock Exchange (LSE: KNOS). For further information, please visit  www.kainos.com .

 

END

 

 

DSHDKDBKNBKDKBD